Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ: JAGX )

0.8670 +0.0070 (+0.81%)
Streaming Delayed Price Updated: 11:20 AM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 113,214
Open 0.8972
Bid (Size) 0.8670 (1)
Ask (Size) 0.8800 (5)
Prev. Close 0.8600
Today's Range 0.8660 - 0.9231
52wk Range 0.8400 - 21.60
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase
Via ACCESSWIRE

Performance

YTD
-20.46%
-20.46%
1 Month
-5.35%
-5.35%
3 Month
-29.51%
-29.51%
6 Month
-78.91%
-78.91%
1 Year
-84.84%
-84.84%

More News

Read More
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
Via ACCESSWIRE
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Via ACCESSWIRE
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
Via ACCESSWIRE
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera
Via ACCESSWIRE
Earnings Scheduled For November 13, 2024
Via Benzinga
Jaguar Health Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Exploring Jaguar Health's Earnings Expectations
Via Benzinga
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
Via ACCESSWIRE
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
Via ACCESSWIRE
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)
Via ACCESSWIRE
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
Via ACCESSWIRE
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine
Via ACCESSWIRE
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
Via ACCESSWIRE
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Via ACCESSWIRE
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
Via ACCESSWIRE
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Via ACCESSWIRE
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference
Via ACCESSWIRE
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Via ACCESSWIRE
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
Via ACCESSWIRE
Lisa Conte, CEO of Jaguar Health Inc. (NASDAQ: JAGX), to Present at NobleCon20
Via Investor Brand Network
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Via ACCESSWIRE
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
Via ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.